CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 158 enrolled
Drug / intervention
BD Nano™ PRO +3 moredevice
Likely dose
33G Artsana Insupen Extr3mefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03878758
NCT03878758N/ACompleted

Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs the Artsana Insupen® Extr3me 4mm x 33G, Artsana Insupen® Extr3me 3.5mm x 34G and the Simple Diagnostics Comfort EZ™ 4mm x 33G Pen Needles

Becton, Dickinson and Company·interventional·Posted Mar 18, 2019·Updated Mar 9, 2020

In Brief

A clinical study evaluating BD Nano™ PRO, 33G Artsana Insupen Extr3me, and 2 other interventions for Diabetes. Completed, enrolled 158 participants across 2 sites.

Detailed Summary

This is a subject partially blinded, block randomized, prospective, single-visit, multi-center study to compare user experiences with BD Nano™ PRO pen needle vs. three (3) thinner commercially available comparator pen needles (Artsana Insupen Extr3me 33G, Artsana Insupen Extr3me 34G and the Simple Diagnostics Comfort EZ™ 33G Pen Needles). The study will include up to 146 study subjects having Type 1 or Type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMar 18, 2019
Enrollment StartFeb 7, 2019
Primary CompletionApr 30, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.3 years ago

Interventions

BD Nano™ PROdevice

Insulin Pen needle

33G Artsana Insupen Extr3medevice

Insulin Pen Needle

34G Artsana Insupen Extr3medevice

Insulin Pen Needle

Simple Diagnostics Comfort EZ™device

Insulin Pen Needle